Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
 
CORRESPONDENCE
Ahead of Print

Primary large cell neuroendocrine carcinoma of the prostate in a hormone naive patient: A case report from Taiwan


1 Department of Urology, Taipei Medical University-Shuang Ho Hospital, New Taipei, Taiwan
2 Department of Oncology, Taipei Medical University-Shuang Ho Hospital, New Taipei, Taiwan
3 Department of Pathology, Taipei Medical University-Shuang Ho Hospital, New Taipei, Taiwan

Correspondence Address:
Chen-Hsun Ho,
Department of Urology, Taipei Medical University-Shuang Ho Hospital, No. 291 Jhongjheng Road, Jhonghe, New Taipei 23561
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Large cell neuroendocrine carcinoma (LCNEC) of the prostate is extremely rare. Previously reported cases in the literature were almost exclusively developed in men receiving androgen deprivation therapy for prostate adenocarcinoma. We herein present a case of de novo LCNEC: A 66-year-old male was incidentally diagnosed as LCNEC after he underwent transurethral resection of prostate. The stage was T4N1M1. Therefore, the patient was treated with 6 cycles of cisplatin and etoposide in the following 6 months, which achieved a partial remission. He gave up the chance to eradicate the residual mass. Three months later, the tumor progressed rapidly. In conclusion, LCNEC is a rare prostate cancer. Our experience shows that chemotherapy with etoposide and cisplatin is effective to achieve a significant remission. However, LCNEC is highly malignant in nature, postchemotherapy surgery for the residual mass should be considered.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Tzou KY
    -  Cheng WH
    -  Lee WH
    -  Ho CH
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed621    
    PDF Downloaded23    

Recommend this journal